Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

. At January 31, 2008, the company had $20,063,000 in cash and cash equivalents compared to $16,044,000 at fiscal year end April 30, 2007.

"The past quarter was highlighted by a major milestone in our oncology program, as we dosed the first patients in a Phase II trial evaluating bavituximab in combination with chemotherapy in patients with breast cancer," said Steven W. King, president and CEO of Peregrine. "We also received regulatory approval to initiate two additional bavituximab Phase II cancer trials -- a second breast cancer study and a trial in patients with non-small cell lung cancer, a leading cause of cancer deaths worldwide. Planning for these trials is well underway and we anticipate initiating both studies next month. We also made progress in our Cotara clinical program in patients with glioblastoma multiforme (GBM), today announcing promising data from the ongoing dosimetry and Phase II trials showing that several patients are already surviving longer than the expected six-month median survival time for this patient population, with the longest surviving patient now at 15 months post-treatment. Patients who are continuing in the trials are being monitored for safety and overall survival, and we look forward to providing further updates on these trials going forward. We have also recently expanded the number of clinical sites in the Phase Il study to eight and also added a distinguished brain cancer center and experienced Cotara clinical study site -- the Barrow Neurological Institute -- to our dosimetry study in the U.S."

Mr. King added, "Our initiative to raise awareness for the bavituximab and Cotara programs in the scientific and medical communities scored gains, including an oral presentation covering the clinical experience to date in the bavituximab Phase I cancer program at Angio 2008, an oral presentation of clinical data from our Phase I bavituximab trial in hepatitis C patients at the prestigious 2007 Liver Meeting(R), a recent
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)...  Empire Genomics announced today it has acquired ... genomic biomarker from Cornell University for use in ... in diagnosing and determining treatment for patients with ... prostate cancer (NEPC) is a lethal variant of ... but more commonly arises after hormonal therapy for ...
(Date:5/22/2013)... , May 22, 2013  Superior Controls, Inc. ... 2013" by Business NH Magazine.  For the past ... organizations that distinguish themselves with extraordinary business and ... to receive this honor," said Rick ... with any recognition, this award is a reflection ...
(Date:5/22/2013)... Mass. and NEW ORLEANS ... leader in the field of regenerative medicine, presented new ... economists from Analysis Group (a leading health economics consultancy) ... diabetic foot ulcers (DFU) and venous leg ulcers (VLU) ... The results of this research, which reveal annual costs ...
(Date:5/22/2013)... May 22, 2013 Genedata, a ... biotechnology, drug discovery, and life science research, today ... ™ as its bioinformatics platform for strain ... Genedata will provide AB Enzymes, one of the ... hosted solution of Genedata Selector accompanied by bioinformatics ...
Breaking Biology Technology:Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4
... First, a full disclosure: Ive been hawking the concept of ... couple of years, so its no surprise I would think its ... common ground. , ,Then again, its still something of a ... have to be a student of Wisconsin history to know that ...
... - Who needs a record label? Independent musicians can now ... and sell it five minutes later, courtesy of a new ... technology firm's Web Hosting 2.0 represents a customization expansion over ... users to host their existing Web site with Broadjam, or ...
... Doyle , noting that May 24 is the one-year anniversary ... Bush's ban on federal funding for embryonic stem cell ... , ,Doyle noted that Senate Majority Leader Bill Frist ... to schedule a vote on the Stem Cell Research Enhancement ...
Cached Biology Technology:A (modern) Tale of Two Cities: Milwaukee and Madison inch together 2A (modern) Tale of Two Cities: Milwaukee and Madison inch together 3
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
(Date:5/21/2013)... Mass. , May 21, 2013 Royal ... CX50 xMATRIX, the world,s first portable ultrasound with Philips, ... Echo (ICE) capability. The CX50 xMATRIX with available Live ... Paris at the EuroPCR, official meeting ... May 21-24. Since its launch in 2012, ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... backyard barbecue knows that hot dogs are inexplicably packaged in ... versus 10 hot dog buns. Put in ecological terms, this ... buns are worthless without hot dogs to fill them. ... where phosphorus or nitrogen limits plant production in most ecosystems. ...
... played a major role in an international scientific team ... 12 closely related fruit fly species. As well has ... to evolving immune systems -- the analysis paves the ... From the results of the research, the Cornell scientists ...
... RAND PAPER FINDS DIESEL- AND HYBRID-POWERED VEHICLES CAN ... Cars and light trucks powered by advanced diesel ... benefits than traditional gasoline-powered automobiles, according to a ... research by RAND, a non-profit research organization, also ...
Cached Biology News:At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3International team compares 12 fruit fly genomes 2International team compares 12 fruit fly genomes 3RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos 2RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos 3RAND paper finds diesel, hybrid vehicles can provide more societal benefits than gas-powered autos 4
...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: